PDF(Pubmed)
Abstract：
BACKGROUND: The health and productivity of dairy goats continue to be impacted by gastrointestinal nematodes (GIN) and lungworms (LW). Eprinomectin (EPN) is frequently selected for treatment because it is generally effective and does not require a milk withdrawal period. However, some factors, such as lactation, can have an impact on EPN pharmacokinetics and potentially its efficacy. To evaluate whether this can alter the efficacy of Eprecis® 2%, an eprinomectin injectable solution, a study was performed in lactating goats using the dose currently registered in cattle, sheep and goats (0.2 mg/kg).
METHODS: This study was a blinded, randomized, controlled trial performed according to the VICH guidelines. Eighteen (18) worm-free lactating goats were included and experimentally challenged on day 28 with a mixed culture of infective gastrointestinal and lung nematode larvae (Haemonchus contortus, Trichostrongylus colubriformis, Teladorsagia circumcincta, Dictyocaulus filaria). At D-1, fecal samples were collected to confirm patent infection in all animals. On D0, the goats were randomly allocated into two groups of nine goats; group 1 was treated with Eprecis® 2% at 0.2 mg/kg BW by subcutaneous injection, while group 2 remained untreated. Fecal samples for egg counts were collected from all animals on days 3, 5, 7, 9, 11 and 14. On D14, all goats were killed, and the abomasum, small intestine and lungs were removed, processed and subsampled to record the number and species of worms.
RESULTS: The treatment was well tolerated. After treatment, the arithmetic mean FEC decreased in the treated group and remained < 5 EPG until the end of the study, while the arithmetic mean FEC in the control group remained > 849.0 EPG. At D14, goats in the treated group had very limited or zero total worm counts, whereas all animals from the control group had a high worm burden. The measured efficacy was 100.0% against H. contortus and T. colubriformis, 99.9% against T. circumcincta and 98.0% against D. filaria.
CONCLUSIONS: Eprinomectin (Eprecis®, 20 mg/ml), administered at the label dose (0.2 mg/kg), is highly effective against gastrointestinal nematodes and lungworms in lactating goats.
METHODS: This study was a blinded, randomized, controlled trial performed according to the VICH guidelines. Eighteen (18) worm-free lactating goats were included and experimentally challenged on day 28 with a mixed culture of infective gastrointestinal and lung nematode larvae (Haemonchus contortus, Trichostrongylus colubriformis, Teladorsagia circumcincta, Dictyocaulus filaria). At D-1, fecal samples were collected to confirm patent infection in all animals. On D0, the goats were randomly allocated into two groups of nine goats; group 1 was treated with Eprecis® 2% at 0.2 mg/kg BW by subcutaneous injection, while group 2 remained untreated. Fecal samples for egg counts were collected from all animals on days 3, 5, 7, 9, 11 and 14. On D14, all goats were killed, and the abomasum, small intestine and lungs were removed, processed and subsampled to record the number and species of worms.
RESULTS: The treatment was well tolerated. After treatment, the arithmetic mean FEC decreased in the treated group and remained < 5 EPG until the end of the study, while the arithmetic mean FEC in the control group remained > 849.0 EPG. At D14, goats in the treated group had very limited or zero total worm counts, whereas all animals from the control group had a high worm burden. The measured efficacy was 100.0% against H. contortus and T. colubriformis, 99.9% against T. circumcincta and 98.0% against D. filaria.
CONCLUSIONS: Eprinomectin (Eprecis®, 20 mg/ml), administered at the label dose (0.2 mg/kg), is highly effective against gastrointestinal nematodes and lungworms in lactating goats.
摘要：
背景：奶山羊的健康和生产力继续受到胃肠道线虫（GIN）和肺虫（LW）的影响。经常选择Epinomectin（EPN）进行治疗，因为它通常是有效的，并且不需要停奶期。然而,一些因素,如哺乳，可能对EPN药代动力学和潜在的疗效产生影响。为了评估这是否可以改变Eprecis®2%的疗效，eprinomectin注射液,使用目前在牛中注册的剂量在泌乳山羊中进行了一项研究，绵羊和山羊（0.2mg/kg）。
方法：这项研究是盲目的，随机化，根据VICH指南进行对照试验.包括18只无蠕虫的泌乳山羊，并在第28天用感染性胃肠道和肺线虫幼虫的混合培养物进行实验攻击（Haemonchuscontortus，胶毛刚毛,Teladorsagiacircincta,花叶草）。在D-1,收集粪便样品以确认所有动物中的专利感染。在D0时，将山羊随机分为两组，每组9只；第1组通过皮下注射以0.2mg/kg体重的2%Eprecis®治疗，而第2组仍未治疗。在第3、5、7、9、11和14天从所有动物收集用于卵计数的粪便样品。在D14天，所有山羊都被杀了，和皱胃，小肠和肺被切除，处理和二次采样以记录蠕虫的数量和种类。
结果：治疗耐受性良好。治疗后,算术平均FEC在治疗组下降，并保持<5EPG，直到研究结束，而对照组的算术平均FEC保持>849.0EPG。在D14时，治疗组的山羊的蠕虫总数非常有限或为零，而对照组的所有动物都有很高的蠕虫负担。所测量的对变形H.t.colubriformis的疗效为100.0％，99.9%对T.circincta和98.0%对丝虫。
结论：Epinomectin(Eprecis®，20mg/ml)，以标签剂量（0.2mg/kg）施用，对泌乳山羊中的胃肠道线虫和肺虫非常有效。
方法：这项研究是盲目的，随机化，根据VICH指南进行对照试验.包括18只无蠕虫的泌乳山羊，并在第28天用感染性胃肠道和肺线虫幼虫的混合培养物进行实验攻击（Haemonchuscontortus，胶毛刚毛,Teladorsagiacircincta,花叶草）。在D-1,收集粪便样品以确认所有动物中的专利感染。在D0时，将山羊随机分为两组，每组9只；第1组通过皮下注射以0.2mg/kg体重的2%Eprecis®治疗，而第2组仍未治疗。在第3、5、7、9、11和14天从所有动物收集用于卵计数的粪便样品。在D14天，所有山羊都被杀了，和皱胃，小肠和肺被切除，处理和二次采样以记录蠕虫的数量和种类。
结果：治疗耐受性良好。治疗后,算术平均FEC在治疗组下降，并保持<5EPG，直到研究结束，而对照组的算术平均FEC保持>849.0EPG。在D14时，治疗组的山羊的蠕虫总数非常有限或为零，而对照组的所有动物都有很高的蠕虫负担。所测量的对变形H.t.colubriformis的疗效为100.0％，99.9%对T.circincta和98.0%对丝虫。
结论：Epinomectin(Eprecis®，20mg/ml)，以标签剂量（0.2mg/kg）施用，对泌乳山羊中的胃肠道线虫和肺虫非常有效。
